Interestingly, we found that expression of SHLD1 was positively correlated with survival in GBM patients receiving TMZ, while expression of TRIP13, which dissociates shieldin to promote end resection35, was inversely correlated with survival. The gene discussed is TRIP13; the disease is glioblastoma.